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Chuen Neng Lee, MD,a and Theo Kofidis, MD,a Singapore, Republic of SingaporeDespite the development of mitral valve repair and percuta-
neous mitral procedures, mitral valve replacement (MVR)
is still the first option for 62% and 43.2% to 61% of pa-
tients with mitral regurgitation and mitral stenosis, respec-
tively.1 The implantation of a mitral valve prosthesis,
however, still involves the time-consuming work of suturing
a mitral prosthesis to the mitral annulus. Furthermore, en
bloc removal of the degenerated prosthesis, old sutures,
and pledgets during reoperative MVR carries the risks of
embolism and of injury to the already perforated mitral an-
nulus and relevant structures.
The objectives of the this proof of concept large animal
study were to develop a new type of mitral valve implanta-
tion mechanism and to prove that the novel techniquewould
remarkably reduce operative and cardiac arrest times, sim-
plifying MVR with comparable efficacy and safety.MATERIALS AND METHODS
Novel Sutureless Mitral Valve
The novel sutureless mitral valve (Figure 1) is a 2-component device;
a hinge ring and the modified prosthetic mitral valve (PMV). The proto-
types were fabricated in collaboration with the Biomedical Engineering
Group, Nanyang Polytechnic, Singapore, a non–valve-focused facility.
All parts were manufactured with rapid-prototyping material (Accura Si
50; 3D Systems, Inc, Rock Hill, SC).
The hinge ring. This external hinge ring is designed for permanent
anchoring to the mitral annulus and functions as the hinge mechanism.
The PMV. The PMV portion could be compatible with any commer-
cially available mitral prosthesis, with the fabric suture ring removed and
2 new indentations added on the outer side of the valve housing ring to en-
gage with the prominences on the hinge ring. In this study, we produced
a prototype that mimicked a size 27 conventional mitral bileaflet disk
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Fourteen female Yorkshire pigs, weighing 55 to 75 kg, were divided into
control (n¼ 6) and prototype (n¼ 8) groups. Animals in the control group
received a size 27 conventional mitral valve prosthesis, whereas the ones in
the study group received our prototype. The protocol was approved by the
institutional animal care and use committee of the National University of
Singapore.
Surgical Technique
After median sternotomy, cardiopulmonary bypass was established.
After aortic crossclamping and institution of cardioplegia, the left atrium
was opened and the mitral leaflets were excised, leaving behind a rim of 5
mm. In the control group, the mitral leaflets were excised. Sutures were
inserted into the mitral annulus and the mitral prosthesis, followed by
knot tying.
In the prototype group, the hinge ring was mounted on the valve holder
and introduced into the left ventricle through the mitral annulus to the level
at which the pins were just below the annulus. One by one, 12 pins were
punched through the mitral annulus. When all 12 pins were in good posi-
tion, the retainer ring was placed on top of the prototype hinge ring so
that the pins could fit into the corresponding holes of the ring in the atrial
side. The pins were then bent down against the retainer ring, by doing so
pulling the hinge ring and retainer ring closer and thereby clamping the an-
nulus and leaflet tissue in between. The prosthesis was then inserted,
twisted, and clicked into position. Anchoring sutures and a valve holder
were removed, and leaflet movement was checked. No valve suture was
used. The left atrial wall was closed.
The animals were weaned from cardiopulmonary bypass in the usual
fashion. The implanted valves were assessed by epicardial echocardiog-
raphy (GE Vivid-i, 1.5- to 3.6-MHz transducer; GE Healthcare, Chalfont
St Giles, UK). The animals were killed 1 hour after termination of car-
diopulmonary bypass, and the hearts were harvested for gross examina-
tion. One animal was used to test the feasibility of reimplantation of the
prosthesis. That animal’s heart was put back on cardiopulmonary by-
pass, after which it was arrested and the left atrium reopened. The im-
planted PMV was untwisted and taken out. A new PMV was mounted on
the valve holder and then inserted into the stable position inside the
hinge ring in a twist-and-click fashion, resembling a bayonet
mechanism.RESULTS
The implantation and aortic crossclamp times of the pro-
totype group were significantly shorter than those of the
control group at 26.4  4.6 minutes versus 12.4  3.7 min-
utes (P ¼ .0005) and 43.8  8.5 minutes versus 29.4  5.1
minutes (P ¼ .014), respectively. Implantation time was re-
duced by 14 minutes in the prototype group (Table 1).
Electrocardiography did not show any signs of atrioven-
tricular block or ST segment changes. On echocardiogra-
phy, no paraprosthetic leak was seen. There was a mild
central leak arising between the leaflets of the prototype.rdiovascular Surgery c Volume 143, Number 4 985
FIGURE 1. Design and prototype of the new valve. A, Design of the new valve. B, The manufactured prototype before implantation. The hinge ring con-
sists of an outer piece carrying an array of pins (1a) and an inner piece carrying prominences (1b). The pins go through a series of holes in the inner piece
when the 2 pieces are assembled before implantation. The assembled hinge ring with straight and bent pins (1). The retainer ring carries an array of holes to
align with the pins from the atrial side of the mitral annulus, after the pins puncture through the real annulus (2). The mitral bileaflet disk prosthetic valve,
with 2 indentations for engagement with prominences on the hinge ring (3). The valve holder (4). Prosthetic valve is mounted on the valve holder (5). The
pins will be later bent to hold the rings together and attach to the annulus (6, 7). The prosthetic valve is inserted into the hinge ring in a twist-and-click
fashion, resembling a bayonet mechanism (6). Removal of prosthetic valve can be done simply by twisting and pulling out, in the opposite direction.
C, The prototype after implantation in the mitral position: atrial view (7) and ventricular view (8) of the prototype after implantation. The prototype attached
firmly to the mitral annulus. The annular tissue was intact. Note that the healthy valve tissue of the pigs is much thinner and more fragile than that in human
beings.
Brief Research ReportPost mortem gross examination demonstrated that the
valve was attached firmly to the annulus. Wherever the
pins went through the annulus, the tissue was intact
(Figure 1, C). The total crossclamp time of reimplantationTABLE 1. Surgical time of control and prototype groups
Time
Control
(n ¼ 5)
Prototype
(n ¼ 8)
P
value
Aortic crossclamp time (min) 43.8  8.5 29.4  5.1 .014
Implantation time (min) 26.4  4.6 12.4  3.7 .0005
Time of stitching sutures to
annulus (min)
20.2  3.5 0
All data are mean  SD.
986 The Journal of Thoracic and Cardiovascular Surgwas 8 minutes. On post mortem gross examination, we did
examine the anatomy of aortic valve, aortic annulus, and
circumflex artery, and we found no injury to the mentioned
structures.DISCUSSION
Most surgeons manage to replace the mitral valve with
a crossclamp time ranging from 74 to 93 minutes.2,3 The
crossclamp time in our prototype group was significantly
shorter (29.4  5.1 minutes), because any time for
suturing and tying the knots was omitted (Table 1). It
should be noted that the operative duration until opening
of the atrium remained the same (data not shown). Whereery c April 2012
Brief Research Reportthe operation is faster is at the point of, and during, valve
implantation. Surgical time could be further reduced after
a reasonable learning curve. MVR with our device should
be feasible with a single shot of cardioplegia. Of note,
there was a noticeable extension of the implantation and
crossclamp times after the 4th pig (prototype group), as
a result of the change in surgeon from an experienced con-
sultant to a resident. The sutureless design might be of
benefit in minimally invasive mitral surgery, because it
helps avoid the painstaking work of suturing and knot
pushing.
Historically, the Magovern-Cromie sutureless valve,
a caged-ball prosthesis invented in the era of lower quality
of cardiopulmonary bypass in the early 1960s, was the first
sutureless valvular prosthesis. Although it helped signifi-
cantly to shorten bypass time with low rate of paravalvular
leak,4,5 its absence in current practice could be attributed
to the advent of better quality cardiopulmonary bypass,
which allows longer and safer crossclamp times, or to
the disadvantages of the caged-ball valve design in itself,
including a higher incidence of ball malfunction and
thromboembolism.4 Moreover, this valve was more suit-
able for the aortic position, but clamping the heart tissue
beyond the real annulus by the clawlike pins could cause
higher rates of conduction defect.5 Even in the current
era of advanced cardiopulmonary bypass, there is still
abundant evidence that longer cardiac arrest times are as-
sociated with increased risks of atrioventricular block6
and death,7 so a sutureless prosthesis continues to have
value.
Our 2-component valve housing apparatus, which con-
sists of a hinge permanently attaching to the annulus and
an exchangeable valve carrying the leaflets, is different
from the previously described 2-component ValveXchange
device8 in 2 respects. First, any existing prostheses, either
mechanical or bioprosthetic, could be modified to fit into
our hinge, and second, the 2 components can be assembled
with a bayonetlike twist-and-click mechanism.
Next, our goal is to produce a simple and reliable assem-
bly mechanism. We found that the proposed bayonet mech-
anism is simple, reliable, durable, and, more importantly,
safe. As usual, of course, this assembling mechanism will
be subjected to various future modifications. Various suture-
less hinge mechanisms are to be found during intellectual
property background research, for instance at the United
States Patent and Trademark Office. The intellectual prop-
erty on which this prototype technology was based was gen-
erated by the primary investigator (T.K.), who designed this
project.
Bending of the pins evenly against the retainer ring and
slightly inward could be safe and induce sufficient force
for the retainer ring to grasp and hold the annular tissue.
This force prevents paravalvular leak or laceration of annu-
lar tissue surrounding the pins and reinforces the anchoringThe Journal of Thoracic and Caof the valve to the annulus, as demonstrated by the lack of
paravalvular leakage in echocardiographic and postmortem
gross examinations.
Calcified, rheumatic mitral stenosis is one the of major
clinical challenges that our proof of concept animal study
has not yet addressed. A thick and calcified annulus might
cause great difficulty in piercing with the pins, improper
alignment of the pins to the holes in the retainer ring,
and paravalvular leak. This device might therefore first
be used to address degenerative mitral regurgitation and
noncalcified mitral stenosis. Calcified valve diseases
should be an objective of the next steps of the study, in
which further modification of the prototype (eg, a better
penetrating pin, a pledgetlike ring layer) and decalcifica-
tion and implantation techniques can be studied. Further
ring attachment mechanisms, such as magnetic force,
are being investigated. Surgical experience with both con-
ventional devices and our new device could be useful in
deciding which valve is more appropriate in cases in
which the potential benefit our new prosthesis in reoper-
ative MVR in the future should be considered. Other op-
tions could included the use of the twist-and-click
bayonet mechanism only, with a conventional fabric
ring used instead of the pins to suture to the mitral
annulus.
Limitations of the Study and Perspective
The rapid-prototyping material used in this study, Accura
Si 50, is inferior to the usual materials used in heart valve
components (titanium, bicarbon layers, etc). The prototype
was therefore thick and less suitable for transprosthetic
pressure gradient evaluation, long-term implantation, and
handling. The nonsurvival animal model used for this test
lacks long-term follow-up data, including chronic changes
around the prosthesis and ensuing challenges in reoperative
MVR. Finally, our number of subjects was relatively small.
These are acceptable limitations in a study that is only
a proof of concept.
On the basis of the promising preliminary results, a more
specifically experienced valve manufacturer will be en-
gaged to produce the prosthesis for the long-term study.
The new design, with a slimmer profile and more durable
material, will accommodate both conventional mechanical
and biologic valves of different sizes. A survival study
will investigate the long-term durability and behavior of
the device and will define the amount of coagulation
necessary.
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